Hyperhomocysteinemia as a risk factor for venous thrombosis.

T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinemia, but this polymorphism does not seem to be a risk factor for venous thrombosis. Studies on the interaction between hyperhomocysteinemia and other thrombotic risk factors are conflicting. Little is known about the pathophysiology of venous thrombosis in hyperhomocysteinemia. Several mechanisms proposed for vascular disease may be applied to venous thrombosis as well. However, up to now there is no satisfying model which might explain a thrombophilic state at plasma homocysteine concentrations in the range of mild hyperhomocysteinemia. The results of a first clinical intervention study are expected in 2002. As the results are pending, clinicians could perform homocysteine measurements in patients with venous thrombosis if screening for thrombophilia is indicated. Vitamin supplementation could be prescribed if homocysteine levels are elevated. However, the patient should be informed about the uncertainty of the benefits of vitamin supplementation. -->
Number of References: 46
Substance Nomenclature: 0 (factor V Leiden)
9001-24-5 (Factor V)
EC 1.5.- (Oxidoreductases Acting on CH-NH Group Donors)
EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
Entry Date(s): Date Created: 20011011 Date Completed: 20020306 Latest Revision: 20161018
Update Code: 20221213
DOI: 10.1515/CCLM.2001.117
PMID: 11592438
Autor: den Heijer M; Department of Endocrinology, University Medical Center Nijmegen, The Netherlands. m.denheijer@endo.azn.nl, Keijzer MB
Jazyk: angličtina
Zdroj: Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2001 Aug; Vol. 39 (8), pp. 710-3.
DOI: 10.1515/CCLM.2001.117
Abstrakt: Classical homocystinuria is associated with arterial vascular diseases and venous thrombosis. In the last decade, several studies have been published indicating that even mild hyperhomocysteinemia is a risk factor for venous thrombosis. The 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinemia, but this polymorphism does not seem to be a risk factor for venous thrombosis. Studies on the interaction between hyperhomocysteinemia and other thrombotic risk factors are conflicting. Little is known about the pathophysiology of venous thrombosis in hyperhomocysteinemia. Several mechanisms proposed for vascular disease may be applied to venous thrombosis as well. However, up to now there is no satisfying model which might explain a thrombophilic state at plasma homocysteine concentrations in the range of mild hyperhomocysteinemia. The results of a first clinical intervention study are expected in 2002. As the results are pending, clinicians could perform homocysteine measurements in patients with venous thrombosis if screening for thrombophilia is indicated. Vitamin supplementation could be prescribed if homocysteine levels are elevated. However, the patient should be informed about the uncertainty of the benefits of vitamin supplementation.
Databáze: MEDLINE
Externí odkaz: